SGLT2 inhibitors for diabetes may cause ketoacidosis

The FDA just came out with a warning on the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors, including canagliflozin dapagliflozin, and empagliflozin (and the combo drugs including them) because of 20 cases of ketoacidosis. these drugs lead to increased urinary excretion of glucose, thereby lowering hemoglobin A1C. see http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm​ for the press release. findings of FDA:

--from March 2013 to June 2014, there were 20 cases of ketoacidosis reported requiring emergency room visits, an unusual finding in type 2 diabetes. and there have been additional reports since June 2014.
--1/2 the cases did not have any typical DKA triggering factors, such as acute illness (urinary tract infection, urosepsis, gastroenteritis, influenza, trauma), reduced caloric or fluid intake, reduced insulin dose; also no factors associated with high anion-gap acidosis (hypovolemia, acute renal failure, hypoxemia, reduced oral intake, history of alcohol use)
--of note, the glucose levels in the patients were "only mildly elevated at less than 200 mg/dL in some reports, while patients with type 1 diabetes who have DKA typically have glucose levels greater than 250 mg/dL."
--median time to development of DKA was 2 weeks after initiation of drug therapy with SGLT2 inhibitor, but the spread was great (range 1 to 175 days) [and may be much greater as we are more alert to this association and discover more cases]
--the FDA with continue to monitor these drugs to see if there needs to be changes in labeling.

so, as I've mentioned before, I am really reluctant to use these new-fangled drugs. in part because they are new and untested long-term (and this is a case in point). in part because none of them have looked at the important clinical endpoints (death, heart disease, microvascular complications, etc) but only at the effect on the surrogate marker of hemoglobin A1C. and, in part, because of the hassle of getting prior approvals from insurance companies to use these new and expensive meds. the other take-home message for us is to be alert to the possibility of DKA even in patients with blood sugar <200 mg/dL...

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more